CY1109099T1 - Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων - Google Patents

Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων

Info

Publication number
CY1109099T1
CY1109099T1 CY20091100437T CY091100437T CY1109099T1 CY 1109099 T1 CY1109099 T1 CY 1109099T1 CY 20091100437 T CY20091100437 T CY 20091100437T CY 091100437 T CY091100437 T CY 091100437T CY 1109099 T1 CY1109099 T1 CY 1109099T1
Authority
CY
Cyprus
Prior art keywords
csf
cells
cell
dendritic cells
monocytes
Prior art date
Application number
CY20091100437T
Other languages
English (en)
Inventor
Benjamin A Tjoa
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of CY1109099T1 publication Critical patent/CY1109099T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/70—Non-animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/12—Glass

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση προσδιόρισε ότι δενδριτικά κύτταρα θα μπορούσαν να ληφθούν από διάφορες πηγές που συμπεριλαμβάνουν μονοκύτταρα περιφερικού αίματος παρουσία μόνο GM-CSF χωρίς άλλες κυτοκίνες εάν τα μονοκύτταρα δεν ήταν ενεργοποιημένα. Με αποτροπή ενεργοποίησης, όπως με αποτροπή σύνδεσης των κυττάρων στην επιφάνεια του δοχείου καλλιέργειας, τα μονοκύτταρα δεν απαιτούν την παρουσία επιπρόσθετων κυτοκινών, όπως IL-4 ή IL-13, για να αποτραπεί διαφοροποίηση σε κύτταρο μη-δενδριτικής προέλευσης. Τα ανώριμα DCs που δημιουργούνται και διατηρούνται με αυτό τον τρόπο ήταν DC14ˉ και εξέφραζαν υψηλά επίπεδα CD1a. Κατά την ωρίμανση δι' επαφής με παράγοντα όπως, για παράδειγμα, BCG και INFγ, τα κύτταρα προδριορίσθηκε ότι εκφράζουν μόρια επιφάνειας τυπικά των ώριμων δενδριτικών κυττάρων που είναι καθαρισμένα με προηγούμενες μεθόδους και που καλλιεργήθηκαν παρουσία GM-CSF και IL-4. Τα ώριμα δενδριτικά κύτταρα που παρήχθησαν από μονοκύτταρα χωρίς ενεργοποίηση και που καλλιεργήθηκαν σε GM-CSF μόνο είναι κατάλληλα για χρήση σε μεθόδους ανοσοθεραπείας με βάση δενδριτικά κύτταρα, όπως για χρήση στην θεραπεία ασθένειας, που συμπεριλαμβάνει καρκίνο.
CY20091100437T 2003-02-27 2009-04-14 Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων CY1109099T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45101503P 2003-02-27 2003-02-27
EP04715780A EP1604016B1 (en) 2003-02-27 2004-02-27 Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines

Publications (1)

Publication Number Publication Date
CY1109099T1 true CY1109099T1 (el) 2014-07-02

Family

ID=32927693

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100437T CY1109099T1 (el) 2003-02-27 2009-04-14 Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων

Country Status (21)

Country Link
US (4) US8389278B2 (el)
EP (1) EP1604016B1 (el)
JP (1) JP4762887B2 (el)
KR (2) KR20110106474A (el)
CN (1) CN1784488B (el)
AT (1) ATE420946T1 (el)
AU (2) AU2004214896A1 (el)
BR (1) BRPI0407900A (el)
CA (1) CA2517295C (el)
CY (1) CY1109099T1 (el)
DE (1) DE602004019057D1 (el)
DK (1) DK1604016T3 (el)
ES (1) ES2321939T3 (el)
HK (1) HK1086597A1 (el)
IL (1) IL170512A (el)
MX (1) MXPA05009178A (el)
NZ (1) NZ542071A (el)
PL (1) PL209998B1 (el)
RU (1) RU2364625C2 (el)
TW (1) TW200506061A (el)
WO (1) WO2004076651A2 (el)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
BRPI0317064B8 (pt) * 2002-12-06 2021-05-25 Northwest Biotherapeutics Inc composições compreendendo células dendríticas parcialmente amadurecidas in vitro
JP2007507543A (ja) * 2003-10-06 2007-03-29 セダーズ−シナイ メディカル センター 樹状細胞治療によって誘導されるｔ細胞アネルギーを予防するためのｃｏｘ−２インヒビターの使用
EP1676132B1 (en) * 2003-10-21 2014-01-22 Cedars-Sinai Medical Center Combination of chemotherapy and administration of glioma-antigen-pulsed dendritic cells in the treatment of glioma
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
KR101368035B1 (ko) 2005-04-08 2014-02-26 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
AU2006321794A1 (en) * 2005-12-08 2007-06-14 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP1806395A1 (en) * 2006-01-06 2007-07-11 Stichting Sanquin Bloedvoorziening Maturation of dendritic cells
WO2008039874A2 (en) * 2006-09-26 2008-04-03 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
EP1920781B1 (en) * 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
KR100896747B1 (ko) 2007-05-30 2009-05-11 동아대학교 산학협력단 후코이단 또는 그 유사체를 함유하는 수지상 세포의 성숙화유도용 조성물
WO2009155332A1 (en) * 2008-06-17 2009-12-23 Cedars-Sinai Medical Center Use of toll-like receptor ligands as adjuvants to vaccination therapy for brain tumors
EP2328923B1 (en) * 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133 epitopes
JP2010063404A (ja) * 2008-09-10 2010-03-25 Olympus Corp 幹細胞の分離方法
FR2940451B1 (fr) * 2008-12-18 2014-09-12 Proteus Procede d'evaluation de l'immunogenicite des proteines
WO2010129895A2 (en) * 2009-05-07 2010-11-11 Immunocellular Therapeutics, Ltd. Cd133 epitopes
AU2010275443B2 (en) * 2009-07-24 2016-05-12 Rhode Island Hospital Dendritic cell vaccines for asparaginyl- beta - hydroxylase expressing tumors
AU2010307075B2 (en) * 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
AU2011227447B2 (en) * 2010-03-15 2016-04-14 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
RU2458985C1 (ru) * 2011-03-18 2012-08-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт клинической иммунологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИКИ" СО РАМН) Способ генерации антиген-специфических цитотоксических клеток с противоопухолевой активностью
EP2749639B1 (en) * 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN104098652B (zh) * 2014-07-23 2016-11-09 国家纳米科学中心 一种抑制肿瘤转移的多肽和多肽复合物、其制备方法及其应用
CN106029683B (zh) * 2014-07-23 2020-11-10 国家纳米科学中心 一种抑制肿瘤转移和治疗白血病的多肽和多肽复合物、其制备方法及其应用
JP6985939B2 (ja) * 2015-06-30 2021-12-22 ノースウエスト バイオセラピューティクス，インコーポレイティド 改善または増大した抗腫瘍免疫応答を誘導する最適に活性化された樹状細胞
BR112018005180B1 (pt) * 2015-09-15 2023-11-28 Northwest Biotherapeutics, Inc Método in vitro para determinar a potência imunoterapêutica de uma composição de células dendríticas humanas ativas e não totalmente maduras, método in vitro para selecionar um paciente com um tumor sólido que responderá ou não responderá à administração da composição de células dendríticas humanas ativas e não totalmente maduras derivadas do paciente e método in vitro para selecionar um agente de maturação de célula dendrítica para produzir células dendríticas humanas ativas e não totalmente maduras com potência imunoterapêutica aumentada
CN105483084A (zh) * 2016-01-04 2016-04-13 英普乐孚生物技术(上海)有限公司 肿瘤抗原靶向性dc细胞的制备方法
KR102159766B1 (ko) * 2018-11-12 2020-09-24 조선대학교산학협력단 홍조류추출물을 이용한 미성숙수지상세포 분화유도용 배지조성물 및 미성숙수지상세포 분화유도방법
SG11202110970QA (en) * 2019-04-03 2021-10-28 Akron Biotechnology Llc Cryopreservation and cell culture media
CA3148229A1 (en) * 2019-07-12 2021-01-21 Kyushu University, National University Corporation Development of therapy for improving myocardial contraction and method for inhibiting cardiomyocyte death
JP2024515388A (ja) * 2021-05-07 2024-04-09 ナノファエンテック カンパニー リミテッド 樹状細胞の培養方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法
US20230227780A1 (en) * 2022-01-20 2023-07-20 3T Biosciences, Inc. T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE72829T1 (de) * 1985-06-11 1992-03-15 Us Commerce In einem serumfreien medium in suspension kultivierte humane monozyten.
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US6010905A (en) * 1995-01-27 2000-01-04 The United States Of America As Represented By The Department Of Health & Human Services Method for inducing monocytes to exhibit the phenotype of activated myeloid dendritic cells
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
WO2003010292A2 (en) 2001-07-25 2003-02-06 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
EP1441591B1 (en) * 2001-09-06 2016-06-29 NorthWest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
US7695627B2 (en) 2002-06-19 2010-04-13 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for leukocyte enrichment
EP1597356A4 (en) * 2003-02-10 2007-07-11 Northwest Biotherapeutics Inc CELLS HAVING THE CD14 + ANTIGEN OF CULTURE

Also Published As

Publication number Publication date
IL170512A (en) 2013-12-31
AU2010201319A1 (en) 2010-04-29
US9102917B2 (en) 2015-08-11
WO2004076651A3 (en) 2005-03-10
EP1604016B1 (en) 2009-01-14
AU2004214896A1 (en) 2004-09-10
KR20110106474A (ko) 2011-09-28
US20210102169A1 (en) 2021-04-08
CA2517295A1 (en) 2004-09-10
TW200506061A (en) 2005-02-16
EP1604016A2 (en) 2005-12-14
CN1784488B (zh) 2010-07-28
US11827903B2 (en) 2023-11-28
US10731130B2 (en) 2020-08-04
CN1784488A (zh) 2006-06-07
CA2517295C (en) 2016-01-12
US20040203143A1 (en) 2004-10-14
DE602004019057D1 (de) 2009-03-05
WO2004076651A2 (en) 2004-09-10
BRPI0407900A (pt) 2006-03-21
MXPA05009178A (es) 2006-03-08
US20160024472A1 (en) 2016-01-28
ATE420946T1 (de) 2009-01-15
PL209998B1 (pl) 2011-11-30
DK1604016T3 (da) 2009-05-18
KR101201875B1 (ko) 2012-11-15
KR20050107471A (ko) 2005-11-11
US8389278B2 (en) 2013-03-05
AU2010201319B2 (en) 2012-09-06
RU2005129561A (ru) 2006-03-10
US20130273654A1 (en) 2013-10-17
RU2364625C2 (ru) 2009-08-20
JP2006519021A (ja) 2006-08-24
JP4762887B2 (ja) 2011-08-31
PL378291A1 (pl) 2006-03-20
HK1086597A1 (en) 2006-09-22
EP1604016A4 (en) 2006-03-08
ES2321939T3 (es) 2009-06-15
NZ542071A (en) 2007-11-30

Similar Documents

Publication Publication Date Title
CY1109099T1 (el) Δημιουργια δενδριτικων κυτταρων απο μονοκυτταρικα δενδριτικα προδρομικα κυτταρα με gm-csf απουσια επιπροσθετων κυτοκινων
Olsson et al. Priming of human myeloid leukemic cell lines HL-60 and U-937 with retinoic acid for differentiation effects of cyclic adenosine 3′: 5′-monophosphate-inducing agents and a T-lymphocyte-derived differentiation factor
BRPI0212545B8 (pt) método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t
CY1122390T1 (el) Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων
NZ598657A (en) Anti-il-6 antibodies, compositions, methods and uses
ATE268812T1 (de) Methode und zusammensetzungen zum erlangen reifer dendritischer zellen
ATE484578T1 (de) Erzeugung allorestriktiver spezifischer t-zellen
BR9815761A (pt) Processo a vácuo para a fabricação de copolìmeros de siloxano-oxialquileno
ATE407138T1 (de) Verfahren zur herstellung interferierender rna- moleküle in säugetierzellen und therapeutische anwendungen solcher moleküle
DK0633929T3 (da) Fremgangsmåde til in vitro proliferation af dendritcelleforstadier og deres anvendelse til at producere immunogener
Highfill et al. Multipotent adult progenitor cells can suppress graft-versus-host disease via prostaglandin E2 synthesis and only if localized to sites of allopriming
WO2005028626A3 (en) Cell culture media
Lindqvist et al. T regulatory cells in B‐cell malignancy–tumour support or kiss of death?
DE60108661D1 (de) Herstellung und verwendung von dendritischen zellen
DE69738822D1 (de) NEUES SÄUGETIERGEN bc1-w, WELCHES ZUR bc1-2 FAMILIE APOPTOSE-KONTROLLIERENDER GENE GEHÖRT
DE60229960D1 (de) Herstellung kultivierter menschlicher mastzellen und basophilen zur hochdurchsatz-entdeckung kleiner arzneistoffmoleküle
DE3855634T2 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
ATE456649T1 (de) Verwendung allogener zelllinien zur beladung antigen-präsentierender zellen zur auslösung von immunantworten
AU2001259744A1 (en) Compositions and methods for producing antigen-presenting cells
Chaperot et al. Differentiation of anti‐tumour cytotoxic T lymphocytes from autologous peripheral blood lymphocytes in non‐Hodgkin's lymphomas
HK1099026A1 (en) Synthesis of spongosine
KR20070057873A (ko) 면역부활제, 그 생성 방법 및 생성 장치
Fleming et al. Lifespan, oxygen consumption and hydroxyl radical scavenging capacity of two strains of Drosophila melanogaster
WO2004013299A3 (en) Methods for the production of cells and mammals with desired genetic modifications
Hammon IDH mutations as immune target and their effect on dendritic cell differentiation and metabolism